Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $46.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a research note on Monday, November 4th.

Anavex Life Sciences Trading Up 0.2 %

Anavex Life Sciences stock opened at $9.13 on Monday. The business’s 50 day simple moving average is $6.46 and its 200 day simple moving average is $5.58. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $10.45. The company has a market cap of $774.22 million, a price-to-earnings ratio of -18.26 and a beta of 0.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AVXL. The Manufacturers Life Insurance Company lifted its position in shares of Anavex Life Sciences by 8.5% during the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 2,401 shares in the last quarter. Private Advisor Group LLC lifted its holdings in Anavex Life Sciences by 10.3% during the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 4,442 shares in the last quarter. Fiduciary Alliance LLC boosted its stake in Anavex Life Sciences by 45.2% in the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,000 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Anavex Life Sciences by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 6,366 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 7,421 shares during the period. 31.55% of the stock is owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.